RxDoctor Payments Data

Claude Galphin

Nephrology · Chattanooga, TNNPI 1700883816

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,878 of the $3,711 with a category attached, or 77.6%. 12 manufacturers reported payments, led by Boehringer Ingelheim at 58.3% of the total. 2025 is the largest year on record at $2,165, 9.6 times the $226 reported in 2019.

$3,711in general payments, 2019–2025

Across 34 payments — averaging $109.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • CSL Behring$1K
  • AstraZeneca$96
  • Otsuka America Pharmaceutical, Inc.$91
  • Vifor Pharma, Inc.$42
  • Mallinckrodt Hospital Products Inc.$30
  • plus $106 from 6 others
$2,003,486in research payments, 2019–2025

Across 749 payments — averaging $2674.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Akebia Therapeutics Inc$1.1M
  • Vertex$226K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$190K
  • AstraZeneca$156K
  • Gilead$107K
  • CSL Behring$67K
  • plus $168K from 9 others

What the payments were for

  • Travel & lodging$2,87878%
  • Food & beverage$83322%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,711 in reported general payments places this provider in the 75th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Other nephrology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →